Noxopharm Limited NOX.AX Stock
Noxopharm Limited Price Chart
Noxopharm Limited NOX.AX Financial and Trading Overview
Noxopharm Limited stock price | 0.07 AUD |
Previous Close | 0.06 AUD |
Open | 0.06 AUD |
Bid | 0.06 AUD x 0 |
Ask | 0.06 AUD x 0 |
Day's Range | 0.06 - 0.06 AUD |
52 Week Range | 0.04 - 0.32 AUD |
Volume | 360.18K AUD |
Avg. Volume | 559.58K AUD |
Market Cap | 17.53M AUD |
Beta (5Y Monthly) | 1.415708 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.04 AUD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
NOX.AX Valuation Measures
Enterprise Value | 3.5M AUD |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2.5100935 |
Price/Book (mrq) | 0.93749994 |
Enterprise Value/Revenue | 0.501 |
Enterprise Value/EBITDA | -0.337 |
Trading Information
Noxopharm Limited Stock Price History
Beta (5Y Monthly) | 1.415708 |
52-Week Change | -70.95% |
S&P500 52-Week Change | 20.43% |
52 Week High | 0.32 AUD |
52 Week Low | 0.04 AUD |
50-Day Moving Average | 0.06 AUD |
200-Day Moving Average | 0.13 AUD |
NOX.AX Share Statistics
Avg. Volume (3 month) | 559.58K AUD |
Avg. Daily Volume (10-Days) | 595.18K AUD |
Shares Outstanding | 292.24M |
Float | 193.18M |
Short Ratio | N/A |
% Held by Insiders | 33.53% |
% Held by Institutions | 1.03% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | -221.61% |
Operating Margin (ttm) | -152.50% |
Gross Margin | -50.0019% |
EBITDA Margin | -148.59% |
Management Effectiveness
Return on Assets (ttm) | -22.99% |
Return on Equity (ttm) | -59.26% |
Income Statement
Revenue (ttm) | 6.99M AUD |
Revenue Per Share (ttm) | 0.02 AUD |
Quarterly Revenue Growth (yoy) | 87.00% |
Gross Profit (ttm) | -2348769 AUD |
EBITDA | -10380355 AUD |
Net Income Avi to Common (ttm) | -15480665 AUD |
Diluted EPS (ttm) | -0.07 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 11.12M AUD |
Total Cash Per Share (mrq) | 0.04 AUD |
Total Debt (mrq) | 12.1K AUD |
Total Debt/Equity (mrq) | 0.07 AUD |
Current Ratio (mrq) | 5.419 |
Book Value Per Share (mrq) | 0.064 |
Cash Flow Statement
Operating Cash Flow (ttm) | -5280653 AUD |
Levered Free Cash Flow (ttm) | -1310457 AUD |
Profile of Noxopharm Limited
Country | Australia |
State | NSW |
City | Chatswood |
Address | Tower A, The Zenith |
ZIP | 2067 |
Phone | 61 2 9144 2223 |
Website | https://www.noxopharm.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Noxopharm Limited, a drug development company, focuses on developing treatment options for a range of solid tumor cancers and septic shock in Australia and internationally. It primarily develops Veyonda, which is an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also develops DARRT program that is in Phase 1b/2a for the treatment of metastatic castration-resistant prostate cancer and other solid tumors; LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types; and chemotherapy enhancement program (CEP) combined with carboplatin for patients with refractory solid tumors in the breast, head and neck, lung, prostate, and ovaries. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops programs to treat pancreatic cancer and glioblastoma. Noxopharm Limited has a collaboration with Hudson Institute of Medical Research and The Australian National University for the research and development of therapeutic drug against inflammatory disorders. The company was incorporated in 2015 and is based in Chatswood, Australia.
Q&A For Noxopharm Limited Stock
What is a current NOX.AX stock price?
Noxopharm Limited NOX.AX stock price today per share is 0.07 AUD.
How to purchase Noxopharm Limited stock?
You can buy NOX.AX shares on the ASX exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Noxopharm Limited?
The stock symbol or ticker of Noxopharm Limited is NOX.AX.
Which industry does the Noxopharm Limited company belong to?
The Noxopharm Limited industry is Biotechnology.
How many shares does Noxopharm Limited have in circulation?
The max supply of Noxopharm Limited shares is 292.24M.
What is Noxopharm Limited Price to Earnings Ratio (PE Ratio)?
Noxopharm Limited PE Ratio is now.
What was Noxopharm Limited earnings per share over the trailing 12 months (TTM)?
Noxopharm Limited EPS is -0.04 AUD over the trailing 12 months.
Which sector does the Noxopharm Limited company belong to?
The Noxopharm Limited sector is Healthcare.